Nov 20, 2023 17:05 JST

Source: Eisai

LEQEMBI Wins Best New Drug And Clinical Advance of The Year at The Scrip Awards 2023

TOKYO and CAMBRIDGE, Mass., Nov 20, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that Alzheimer’s disease (AD) treatment LEQEMBI® (lecanemab-irmb) was awarded both the Best New Drug and Clinical Advance of the Year for the Phase III Clarity AD study at the Scrip Awards 2023, held by Citeline.

The Scrip Awards, now in its 19th year, celebrates the best innovations and achievements of the international biopharma industry.

The award for Best New Drug recognizes excellence in pharmaceutical development and celebrates LEQEMBI as the first and only treatment approved in Japan and the United States shown to reduce the rate of disease progression and to slow cognitive and functional decline, which acts on the underlying pathology of AD.

The award for Clinical Advance of the Year recognizes the success of a new drug product in a clinical trial that is expected to lead to an advance in healthcare. It was awarded for the success of the Phase III Clarity AD study of LEQEMBI.

Eisai and Biogen deeply appreciate the cooperation of people living with AD and healthcare professionals who participated in LEQEMBI’s clinical studies.

AD is a progressive, fatal disease, and a global healthcare issue that greatly impacts not only the people living with the disease, but also their loved ones, care partners and society. Eisai and Biogen will deliver LEQEMBI to the people with early AD who need it, as well as aim to continue creating impact on global issues surrounding dementia.

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally, with both Eisai and Biogen Inc. (U.S.) co-commercializing and co-promoting the product. Eisai has the final decision-making authority.

Please see full Prescribing Information, including Boxed WARNING in the United States.

For more information, visit www.eisai.com/news/2023/news202370.html

Media Contacts:

Eisai Co., Ltd.
Public Relations Department
TEL: +81 (0)3-3817-5120

Biogen Inc.
Jack Cox + 1-781-464-3260
public.affairs@biogen.com

Source: Eisai
Sectors: BioTech

Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
June 10 2024 17:50 JST
 
Eisai Named to List of The Time 100 Most Influential Companies
June 03 2024 16:08 JST
 
Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform
June 03 2024 14:22 JST
 
LEQEMBI (lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea
May 28 2024 14:19 JST
 
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
May 23 2024 17:07 JST
 
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan
May 22 2024 11:55 JST
 
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
May 15 2024 10:19 JST
 
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures
May 13 2024 16:06 JST
 
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
April 18 2024 09:53 JST
 
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
April 17 2024 15:17 JST
 
More Press release >>

Latest Press Release


More Latest Release >>